Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

“…Similarly, Caminati and colleagues evaluated asthma outcomes in 68 mepolizumab-switched patients treated with benralizumab for a median period of 31 months [30]. In a more recent work, Fyles et al considered a population of 81 SEA patients treated with either mepolizumab or benralizumab for up to 36 months; however, the majority of data were presented for the overall population, and thus, it is not possible to extrapolate the clinical improvements experienced by benralizumab-treated patients for each single outcome [31].…”

“…A marked and long-lasting reduction in exacerbations has been consistently shown across all studies, with impressive results obtained from the Italian ANANKE study, showing reductions of 94.9% and 96.9% in all and severe annual exacerbation rate (AER), respectively, after 96 weeks of treatment [25]. Positive outcomes have also been demonstrated in lung function and OCS reduction; however, the extent and the durability of benralizumab effectiveness on respiratory outcomes for periods longer than 2 years is still uncertain [31,33]. Recently published data from the phase IV randomized clinical trial (RCT) SHAMAL revealed that the benralizumab treatment was associated with a substantial reduction in the dose of background ICS, showcasing an additional clinical benefit of the anti-IL-5R therapy [34].…”

“…To date, the 5-year-long MELTEMI trial represents the longest study evaluating the effects of benralizumab on SEA patients; the results indicated that benralizumab was safe and effective in eliminating exacerbations in up to 59% of patients during the entire extension period (BORA and MELTEMI studies, up to 4 years of treatment) [27]. Few real-life studies have investigated the benralizumab effectiveness over 20-month-4-year-long periods [25,[28][29][30][31][32][33]. A marked and long-lasting reduction in exacerbations has been consistently shown across all studies, with impressive results obtained from the Italian ANANKE study, showing reductions of 94.9% and 96.9% in all and severe annual exacerbation rate (AER), respectively, after 96 weeks of treatment [25].…”